CRISPR Therapeutics AG (CRSP) Common Equity (2015 - 2026)
CRISPR Therapeutics AG (CRSP) posted Common Equity of $1.8 billion for Q1 2026, down 5.58% sequentially from $1.9 billion in Q4 2025, and down 0.8% YoY from $1.8 billion in Q1 2025.
CRISPR Therapeutics AG (CRSP) Common Equity (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Common Equity for 12 years, with the latest figure at $1.8 billion in Q1 2026.
- Quarterly Common Equity fell 0.8% year-over-year to $1.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 billion (down 0.8% YoY) and the FY2025 annual result came in at $1.9 billion, down 0.53% from the prior year.
- Common Equity retreated to $1.8 billion in Q1 2026 per CRSP's latest filing, from $1.9 billion in the prior quarter.
- Over five years, Common Equity peaked at $2.2 billion in Q1 2022 and troughed at $1.7 billion in Q2 2025.
- A 5-year average of $1.9 billion and a median of $1.9 billion in 2025 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 24.34% in 2022, down 22.24% in 2022.
- Over 5 years, Common Equity stood at $1.9 billion in 2022, then grew by 0.39% to $1.9 billion in 2023, then gained by 2.62% to $1.9 billion in 2024, then declined by 0.53% to $1.9 billion in 2025, then decreased by 5.58% to $1.8 billion in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $1.8 billion, $1.9 billion, and $1.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | 1.75 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.75 Bn |
| Mar 31, 2026 | 1.81 Bn |
| Dec 31, 2025 | 1.92 Bn |
| Sep 30, 2025 | 1.92 Bn |
| Jun 30, 2025 | 1.71 Bn |
| Mar 31, 2025 | 1.83 Bn |
| Dec 31, 2024 | 1.93 Bn |
| Sep 30, 2024 | 1.94 Bn |
| Jun 30, 2024 | 1.98 Bn |
| Mar 31, 2024 | 2.08 Bn |
| Dec 31, 2023 | 1.88 Bn |
| Sep 30, 2023 | 1.73 Bn |
| Jun 30, 2023 | 1.82 Bn |
| Mar 31, 2023 | 1.85 Bn |
| Dec 31, 2022 | 1.88 Bn |
| Sep 30, 2022 | 1.95 Bn |
| Jun 30, 2022 | 2.09 Bn |
| Mar 31, 2022 | 2.24 Bn |
| Dec 31, 2021 | 2.40 Bn |
| Sep 30, 2021 | 2.51 Bn |